Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2022-08-05 Director's Dealing
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-08-05 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-05 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 registration statement filed with the SEC by Pacira BioSciences, Inc. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock purchase plans. The document includes details about the registration of additional shares under the company's Amended and Restated 2014 Employee Stock Purchase Plan. It contains legal and regulatory information, indemnification clauses, and signatures of company officers. It is not a financial report, earnings release, or any other type of report listed in the filing definitions. Instead, it is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is a full filing, not a brief announcement or certification.
2022-08-04 English
10-Q - PCRX - 6.30.2022
Interim / Quarterly Report Q2 2022
2022-08-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 3, 2022, by Pacira BioSciences, Inc. It announces the issuance of a press release with financial results for the second quarter ended June 30, 2022. The document explicitly states that the press release is furnished as an exhibit and is not deemed filed for certain regulatory purposes. The content is a current report announcing earnings results, typical of an Earnings Release. The document length is 3389 characters, which is short and consistent with an earnings release announcement rather than a full quarterly report. Therefore, the document is best classified as an Earnings Release (ER).
2022-08-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and includes a press release with preliminary unaudited revenue for a recent quarter. The document is short (3392 characters) and primarily serves to announce the earnings release via a press release (Exhibit 99.1). It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). According to the "Menu vs Meal" rule, since it is a short announcement with a press release attached, it should be classified as an Earnings Release (ER). The Form 8-K is commonly used for earnings releases and similar announcements. Therefore, the best classification is ER with high confidence.
2022-07-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.